GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation )

Inclusion Criteria: * Patients diagnosed with IBD by the usual criteria; both Crohn's and ulcerative colitis disease. * Patients older than 18 years. * In the case of patients with Crohn's disease the indication treatment with anti-TNF it must have been for luminal involvement (no perianal). * Are currently in clinical remission. * The clinical remission period with the drug at non-intensified dose it must have been at least 6 months. The administration of ≥10 mg/kg/8 weeks or 5 mg / kg / ≤ 4 weeks, in the case of infliximab, and 40 mg / week, in the case of adalimumab, is considered an intensified dose. * At the time of inclusion, the patient should be receiving concomitant immunosuppressants (thiopurine or methotrexate) to anti-TNF treatment, and must have received these immunosuppressive drugs at stable doses for at least the last 3 months. * In patients with Crohn's disease or ulcerative colitis disease, at baseline colonoscopy (made up to 3 months prior to the screening visit) should not be "significant" injuries. * In the case of patients with Crohn's ileal or ileocolic disease, in magnetic resonance whole should not be "significant" injuries.(made up to 3 months prior to the screening visit) Exclusion Criteria: * Age less than 18 years. * Patients who have been treated with anti-TNF for other indication than the IBD. * Patients with Crohn's disease in which the indication for treatment with anti-TNF has been the perianal involvement (or luminal and perianal both); or showing active perianal disease at the time of inclusion. * Patients who are not receiving concomitant treatment with immunosuppressants (thiopurine or methotrexate) at the moment (and in the previous 3 months). * Patients undergoing bowel resection surgery; therefore, patients who began anti-TNF therapy to prevent or treat postoperative recurrence in Crohn's disease will be excluded. * Presence of "significant" endoscopic or radiological lesions * Advanced chronic illness or any other condition that prevents the patient from coming to the clinic for monitoring or follow-up. * Patients who are pregnant, breastfeeding or intending to become pregnant during the course of the study. * Refusal to give consent for participation in the study.